
Retatrutide
The one most researchers are excited about — a triple-agonist that works three receptors at once (GLP-1, GIP and glucagon). Across a 48-week trial the placebo group lost about 2% of body weight; the highest retatrutide dose reached roughly 24% — on standard lifestyle guidance, not a crash diet. Still in late-stage clinical trials.


